...
首页> 外文期刊>Hepatology international >Role of steroid minimization in the tacrolimus-based immunosuppressive regimen for liver transplant recipients: a systematic review and meta-analysis of prospective randomized controlled trials
【24h】

Role of steroid minimization in the tacrolimus-based immunosuppressive regimen for liver transplant recipients: a systematic review and meta-analysis of prospective randomized controlled trials

机译:类固醇最小化在他克莫司为基础的肝移植受者免疫抑制方案中的作用:前瞻性随机对照试验的系统评价和荟萃分析

获取原文

摘要

To evaluate the efficacy and safety of early steroid withdrawal or steroid avoidance in the tacrolimus (Tac)-based immunosuppressive regimen for liver transplant recipients. According to the requirements of the Cochrane systematic review, a thorough literature search was performed in the PubMed/MEDLINE and Cochrane electronic databases between 1995 and 2011 using the key words “liver transplantation,” “Tac,” and “steroid free” or “steroid withdrawal,” restricting articles to the English language. Data were processed for a meta-analysis by Stata 12 software. Altogether 17 prospective randomized controlled trials containing 1,980 transplanted patients were included in this study. The overall pooled RR estimates of 1-, 2-, 3-, and 5-year patient and graft survival rates were 0.985, 0.998, 0.995, and 1.100 (95?% CI 0.925–1.048, 0.934–1.067, 0.894–1.107, and 0.968–1.250, respectively), as well as 0.998, 0.993, 0.945, and 1.053, respectively (95?% CI 0.928–1.072, 0.902–1.092, 0.833–1.072, and 0.849–1.307, respectively). The other pooled RR estimates of acute rejection and chronic rejection rates for all enrolled studies were 1.077 and 0.311 (95?% CI 0.864–1.343 and 0.003–37.207). As for secondary predictors, the pooled RR estimates such as HCV recurrence, HCC recurrence, diabetes, hypertension, kidney dysfunction, bacterial infection, and CMV were 1.101, 1.403, 1.836, 1.607, 0.842, 1.096, and 2.280, respectively (95?% CI 0.964–1.257, 0.422–4.688, 1.294–2.606, 0.926–1.228, 0.693–1.022, 0.783–1.533, and 1.500–3.465, respectively). There were no differences between the steroid group and steroid-free group for all clinical observational indices except for the incidence of diabetes (p?=?0.001) and CMV infection (p?
机译:在基于他克莫司(Tac)的肝移植受者免疫抑制方案中评估早期停用类固醇或避免类固醇的疗效和安全性。根据Cochrane系统评价的要求,在1995年至2011年之间,在PubMed / MEDLINE和Cochrane电子数据库中使用关键词“肝移植”,“ Tac”和“不含类固醇”或“类固醇”进行了全面的文献检索。撤回”,将文章限制为英语。通过Stata 12软件对数据进行荟萃分析。本研究共包括17个前瞻性随机对照试验,其中包含1,980名移植患者。 1年,2年,3年和5年患者和移植物存活率的总RR估计值分别为0.985、0.998、0.995和1.100(95%CI 0.925–1.048、0.934–1.067、0.894-1.107,分别为0.968-1.250和0.968-1.250)以及0.998、0.993、0.945和1.053(95%CI分别为0.928-1.072、0.902-1.092、0.833-1.072和0.849-1.307)。所有纳入研究的其他RR对急性排斥和慢性排斥率的合并估计分别为1.077和0.311(95%CI 0.864–1.343和0.003–37.207)。至于二级预测指标,合并的RR估计值分别为HCV复发,HCC复发,糖尿病,高血压,肾功能不全,细菌感染和CMV,分别为1.101、1.403、1.836、1.603、0.842、1.096和2.280(95%)。 CI分别为0.964-1.257、0.422-4.688、1.294-2.606、0.926-1.228、0.693-1.022、0.783-1.53​​3和1.500-3.465)。在所有临床观察指标上,类固醇组和不含类固醇的组之间没有差异,除了糖尿病的发生率(p <= 0.001)和CMV感染(p 0.001)。总而言之,我们的研究表明,在基于Tac的免疫抑制方案中类固醇的快速停用可能不会导致发病率和排斥率的增加。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号